The spectrum of medical therapies to treat COVID-19 continues to evolve and address SARS-CoV-2 variants. Sotrovimab, Tixagevimab/Cilgavimab (Evusheld), Bebtelovimab, Paxlovid and Molnupiravir are therapeutic products available that have received Emergency Use Authorizations (EUAs) from the Food and Drug Administration (FDA) and available to providers in our state.
All therapeutics can be requested via the COVID-19 Therapeutic Allocation Request Form. Sites must have a Healthcare Partner Ordering Portal (HPOP) account to receive shipments. HPOP accounts need to have therapeutic address/hours verified in order to receive product and must report on-hand and dispensed product daily.
For questions related to therapeutics, please reach out to the Washington State Department of Health Medical Countermeasure Team at email@example.com.